Dr. Rajesh Behl is a hematologist in Berkeley, California. He is affiliated with multiple hospitals in the area, including Alta Bates Summit Medical Center and Alta Bates Summit Medical Center - Summit Campus. He received his medical degree from Maulana Azad Medical College and has been in practice for 21 years. He is one of 13 doctors at Alta Bates Summit Medical Center and one of 13 at Alta Bates Summit Medical Center - Summit Campus who specialize in Hematology.
Education & Medical Training
University of Minnesota
Residency, Internal Medicine, 1995–1998
Washington University
Fellowship, Hematology/Oncology, 1998–2001
Maulana Azad Medical College
Class of 1993
Certifications & Licensure
American Board of Internal Medicine
Certified in Internal Medicine
American Board of Internal Medicine
Certified in Medical Oncology
CA State Medical License
Active through 2015
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
BehlR@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant Large B-Cell Lymphoma
Consolidation of First-Line MRD+ Remission with Cema-cel in Patients with LBCL (ALPHA3)
Investigator: Rajesh Behl M.D.
Status: Active, Recruiting
Chronic Lymphocytic Leukemia
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Follicular Lymphoma
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With R
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Lymphoma Mantle Cell GLOBRYTE
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/?Refractory Mantle Cell Lymphoma (GLOBRYTE)
Investigator: Rajesh Behl M.D.
Status: Active, Recruiting
MajesTEC-9
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Particip
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Multiple Myeloma Cervino
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple
Investigator: Rajesh Behl M.D.
Status: Active, Recruiting
Neoadjuvant (EPCORE DLBCL-2)
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydr
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Research Studies
Oral Oncology Medication Adherence Research Pilot: MediConnect
The objective of this research project is to design, implement, and evaluate the impact of a comprehensive oral oncology medication management tool.
Investigators: Rajesh Behl M.D., J.B. Jones PhD, MBA, Xiaowei (Sherry) Yan PhD, MS